Efter 6 måneder viste Aclasta respons hos 96% (169/ 176) og en serum alkalisk phosphatase (SAP) normaliseringsrate hos 89% (156/ 176) sammenlignet med 74% (127/ 171) og 58% (99/ 171) for risedronat (alle p < 0, 001).
After 6 months, Aclasta showed 96% (169/ 176) and 89% (156/ 176) response and serum alkaline phosphatase (SAP) normalisation rates compared to 74% (127/ 171) and 58% (99/ 171) for risedronate (all p < 0.001).